Form 4: Labcorp CEO Receives Significant Equity Awards

Labcorp Holdings Inc. CEO Adam H. Schechter was granted 31,700 non-qualified stock options and 10,440 restricted stock units on February 10, 2026.

Summary

• Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), acquired equity awards on February 10, 2026.
• The awards include 31,700 non-qualified stock options with an exercise price of $284.5 per share.
• These options will vest in three equal annual installments, beginning on February 10, 2027, and expire on February 09, 2036.
• Additionally, Mr. Schechter received 10,440 Restricted Stock Units (RSUs), each representing the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs will also vest in three equal annual installments, starting on February 10, 2027.
• Following these transactions, Mr. Schechter directly beneficially owns 31,700 non-qualified stock options and an aggregate of 25,870 Restricted Stock Units.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it signifies continued alignment of executive incentives with long-term shareholder value through performance-based equity awards.

Positives

• The grant of equity awards aligns the President & CEO's long-term financial interests with those of Labcorp's shareholders, incentivizing sustained company performance.
• The awards are part of the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan, indicating a structured approach to executive compensation.
• The use of a Rule 10b5-1(c) plan demonstrates a pre-planned and transparent approach to insider transactions.

Negatives

• No direct negative implications are present in this routine executive compensation filing.

Risks

• This Form 4 filing does not inherently contain specific risks to the company's operations or financial health; it reports an insider transaction.

Future Outlook

The equity awards granted to the President & CEO are designed to incentivize long-term performance and align executive interests with future shareholder value creation, with vesting schedules extending several years into the future.

Industry Context

StockSavvy.ai notes that equity awards are a common and critical component of executive compensation in the healthcare and diagnostics industry, aligning leadership incentives with long-term shareholder value. This practice is standard across major players in the sector to attract, retain, and motivate top talent.

Comparison to Industry Standards

• StockSavvy.ai notes that grants of this magnitude are typical for CEOs of large-cap companies like Labcorp, which operates in the highly competitive diagnostics and drug development services market.
• Comparable executive compensation packages, which heavily utilize performance-based equity, are observed at industry peers such as Quest Diagnostics (DGX) and Thermo Fisher Scientific (TMO), reflecting a common strategy to link executive pay to company performance and shareholder returns.

Corporate Governance

Related Party Transactions

• The acquisition of non-qualified stock options and Restricted Stock Units by Adam H. Schechter, the President & CEO and a Director, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the interests of the CEO with shareholders, potentially leading to enhanced long-term value creation through incentivized performance.
• Employees (Adam H. Schechter): The grants represent a significant component of executive compensation, providing a direct incentive for performance and retention within the company.

Next Steps

• The non-qualified stock options and Restricted Stock Units will begin to vest in three equal annual installments starting on February 10, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity awards, which is a standard practice to align management incentives with long-term shareholder value. It does not present new fundamental information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Labcorp Holdings Inc., LH, Adam H. Schechter, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Awards, Executive Compensation, Rule 10b5-1